Medtronic announced Friday that FDA has approved the the first MR-conditional cardiac resynchronization therapy defibrillators (CRT-Ds) for the treatment of heart failure in the U.S. The Medtronic ...
PLATINIUM, released simultaneously in both Europe and Japan by LivaNova (formerly Sorin Group), will protect patients from avoidable replacement surgeries and the inherent risk of complications.
Please provide your email address to receive an email when new articles are posted on . Among the features of the new European Society of Cardiology guideline on pacing and cardiac resynchronization ...
The EchoCRT Study Will Investigate the Life-Saving Benefits of Cardiac Resynchronization Therapy in Patients with Heart Failure Who Currently Do Not Receive Device Therapy BERLIN, Germany & LAKE ...
MINNEAPOLIS - Medtronic, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for biventricular (BiV) pacing with Medtronic cardiac resynchronization ...
DUBLIN and BARCELONA, Two real-world analyses featuring the Medtronic plc (NYSE: MDT) AdaptivCRT(TM) algorithm reinforce that its use is linked to a reduction in atrial fibrillation (AF) episodes, as ...
San Francisco, CA - When a heart-failure patient has a defibrillator-equipped cardiac resynchronization therapy (CRT-D) device, antitachycardia pacing (ATP) is preferable to a shock for the treatment ...
A combination defibrillator and cardiac resynchronization device reduced deaths by nearly one-third in patients with mild heart failure in a study that was terminated early on Monday because of its ...
ABBOTT PARK, Ill., Feb. 18, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received CE Mark for the new Gallant™ implantable cardioverter defibrillator (ICD) and cardiac ...
The U.S. cardiac resynchronization therapy market was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. Surge in ...
The major trials that established cardiac resynchronization therapy (CRT) as a treatment for heart failure (HF) with reduced ejection fraction (HFrEF) tended not to include patients who already had ...
The company identified 7 studies that incorporated a cost-effectiveness analysis. It did not rely on these economic studies for its model, but the structure of the de novo model is similar to that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results